There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

The drug aims to address obesity by enhancing fat loss and controlling appetite through its glucagon-like peptide-1 receptor and glucagon receptor activation. Preclinical studies suggest promising ...

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

Berberine, green tea extract and taurine are just some of the ingredients advertised as being able to ‘boost’ GLP-1 levels.

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

GLP-1 (glucagon-like peptide-1) medications reduce appetite by sending signals of fullness to the brain and slowing down ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

President-elect Donald Trump, a Biden administration proposal would require Medicare and Medicaid to cover weight-loss drugs ...